Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Things that seemed impossible, only a few years ago, are happening today. The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford.

Female clinician carrying out a treatment

The trial in Oxford is run by the STRONG research group of the Department of Paediatrics and the MDUK Oxford Neuromuscular Centre led by Professor Laurent Servais. Investigators, families, and the community are excited about the developments for Angelman syndrome in Oxford and look forward to seeing the results of the first of, hopefully, many more trials to come. This is the beginning of a new era for Angelman syndrome, where potential treatments targeting the root cause, the lack of functional UBE3A protein, are reaching the patients’ bedside. 

Angelman syndrome is a rare, genetic disorder, which affects the development of the nervous system. It results in severe developmental delay, balance issues, motor impairment and debilitating seizures.Some individuals with Angelman syndrome are unable to walk and most do not speak. It affects approximately 1 in 12,000 to 1 in 20,000 people globally. Most cases are not inherited, but instead occur spontaneously. With current practices, Angelman syndrome is not routinely detected before or at birth. At this time, there is no approved treatment and individuals are managed with non-specific medication to alleviate symptoms of Angelman syndrome. Affected individuals have a normal lifespan but never become independent adults. The diagnosis has a severe impact on family life, as these individuals need someone to care for them around the clock. Most caregivers must dedicate themselves to the care of their individual diagnosed with Angelman syndrome.

Read the full story on the Department of Paediatrics website

 

Similar stories

Oxford spinout trials revolutionary bioelectronic implant to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their “smart” bioelectronic implants.

COVID-19 is a leading cause of death in children and young people in the US

A new study led by researchers at the University of Oxford’s Department of Computer Science has found that, between 2021 and 2022, COVID-19 was a leading cause of death in children and young people in the United States, ranking eighth overall. The results demonstrate that pharmaceutical and public health interventions should continue to be applied to limit the spread of the coronavirus and protect again severe disease in this age group.

Three or more concussions linked with worse brain function in later life

Experiencing three or more concussions is linked with worsened brain function in later life, according to new research.

New blood test could save lives of heart attack victims

Researchers in the Department of Physiology, Anatomy and Genetics (DPAG) have developed a blood test that measures stress hormone levels after heart attacks. The test – costing just £10 – could ensure patients receive timely life-saving treatment.

COVID-19 increased public trust in science, new survey shows

A survey of over 2000 British adults has found that public trust in science, particularly genetics, increased significantly during the pandemic. However, those with extremely negative attitudes towards science tend to have high self-belief in their own understanding despite low textbook knowledge.

Gero Miesenböck awarded 2023 Japan Prize

Congratulations to Professor Gero Miesenböck, Department of Physiology, Anatomy and Genetics (DPAG), who has been awarded the 2023 Japan Prize in the field of Life Sciences, together with Professor Karl Deisseroth, for pioneering work in the field of optogenetics.